Literature DB >> 33476715

Ectopic expression of microRNA-874 represses epithelial mesenchymal transition through the NF-κB pathway via CCNE1 in cholangiocarcinoma.

Xin Pan1, Gang Wang2, Baoming Wang2.   

Abstract

Cholangiocarcinoma (CC) is a devastating disease associated with poor survival rate. microRNAs (miRNAs) have recently been reported to assume a great role in CC development. This research aims to explore the functions of miR-874 in regulating epithelial mesenchymal transition (EMT) in CC. In obtained CC tissues and cells, miR-784 expression was assessed by RT-qPCR, and CCNE1 expression by RT-qPCR or immunohistochemistry. Dual-luciferase reporter assay was implemented for relationship between miR-784 and CCNE1. The roles of miR-784, CCNE1 and the NF-κB pathway in CC were investigated on human CC cell lines. CCNE1 was found to be highly expressed in CC while miR-874 expression was lowered in CC tissues and cells, thereby suggesting a negative regulatory effect of CCNE1. In QBC939 and RBE cells, overexpressing miR-874 or silencing CCNE1 led to augmented IκBα and E-cadherin expression, but diminished CCNE1, NF-κB, N-cadherin, and Vimentin expression. Moreover, overexpression of miR-874 or CCNE1 silencing led to reduced cell proliferation, invasion, and migration capabilities. In conclusion, we demonstrated that miR-874 negatively regulated CCNE1 to inhibit the NF-κB pathway, thus consequently suppressing EMT in CC. Therefore, the overexpression of miR-874 might bring favorable outcomes for the treatment of CC.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  CCNE1; Cholangiocarcinoma; Epithelial mesenchymal transition; Invasion; MicroRNA-874; Migration; NF-κB pathway

Mesh:

Substances:

Year:  2021        PMID: 33476715     DOI: 10.1016/j.cellsig.2021.109927

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  1 in total

Review 1.  miR-874: An Important Regulator in Human Diseases.

Authors:  Qiudan Zhang; Chenming Zhong; Qianqian Yan; Ling-Hui Zeng; Wei Gao; Shiwei Duan
Journal:  Front Cell Dev Biol       Date:  2022-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.